Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting
- Data demonstrate that uPARAP is widely expressed at high levels across multiple sarcoma subtypes
- Strong overexpression in tumors combined with low expression levels in normal human tissues makes uPARAP an attractive candidate for therapeutic targeting of sarcomas by antibody-drug conjugates (ADCs)
Copenhagen, Denmark, 13 April, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, will be presenting novel data evaluated in co-operation with the Laboratory of Experimental Oncology at KU Leuven/Leuven Cancer Institute on the expression of the novel ADC target uPARAP in Soft Tissue Sarcoma (STS) and Bone Sarcoma at the American Association for Cancer Research (AACR) Annual Meeting, being held in Orlando, Florida on the 14-19 April, 2023.
